Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Vici P, Brandi M, Giotta F, Foggi P, Schittulli F, Di Lauro L, Gebbia N, Massidda B, Filippelli G, Giannarelli D, Di Benedetto A, Mottolese M, Colucci G, Lopez M. Vici P, et al. Among authors: schittulli f. Ann Oncol. 2012 May;23(5):1121-1129. doi: 10.1093/annonc/mdr412. Epub 2011 Sep 28. Ann Oncol. 2012. PMID: 21965475 Free PMC article. Clinical Trial.
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
Brandi M, Vici P, Lopez M, Valerio MR, Giotta F, Gebbia N, Schittulli F, Colucci G; Grupo Oncologico Italia Meridionale. Brandi M, et al. Among authors: schittulli f. Semin Oncol. 2004 Apr;31(2 Suppl 5):13-9. doi: 10.1053/j.seminoncol.2004.03.022. Semin Oncol. 2004. PMID: 15199527 Clinical Trial.
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A. Amadori D, et al. Among authors: schittulli f. Breast Cancer Res Treat. 2011 Feb;125(3):775-84. doi: 10.1007/s10549-010-1257-5. Epub 2010 Dec 4. Breast Cancer Res Treat. 2011. PMID: 21132360 Free article. Clinical Trial.
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, Cufer T, Sieuwerts AM, Talantov D, Span PN, Tjan-Heijnen VC, Zito AF, Specht K, Hoefler H, Golouh R, Schittulli F, Schmitt M, Beex LV, Klijn JG, Wang Y. Foekens JA, et al. Among authors: schittulli f. J Clin Oncol. 2006 Apr 10;24(11):1665-71. doi: 10.1200/JCO.2005.03.9115. Epub 2006 Feb 27. J Clin Oncol. 2006. PMID: 16505412
82 results